Safety profile of 
ICLUSIG (ponatinib) in CP-CML

Explore ICLUSIG safety profile in chronic phase chronic myeloid leukemia

Safety profile in heavily pretreated and TKI-resistant patients with CP-CML.1-3

ICLUSIG safety in CP-CML is supported by two pivotal trials: OPTIC, which established an optimized dose-reduction strategy  (45 mg → 15 mg upon achievement of ≤1% BCR::ABL1IS),1,3 and PACE, which provides long-term safety follow-up data in heavily pretreated patients.1,2 OPTIC was built with an optimized dosing strategy designed to manage tolerability without compromising efficacy.3

OPTIC trial safety profile of ICLUSIG in CML

PACE trial safety profile of ICLUSIG in CML

BCR::ABL1IS=BCR::ABL1 International Scale; CP-CML=chronic-phase chronic myeloid leukemia.

CML Patient Profiles

""

CML resources and support

""